The rapid expansion of the metabolic drug market has created severe bottlenecks in sterile injectable manufacturing capacity. In response, pharmaceutical developers are committing multi-billion-dollar investments to acquire and retrofit contract development and manufacturing facilities.
Production Capacity
Industry supply chain data indicates that fill-finish capacity constraints will persist through late 2026. Companies are prioritizing vertical integration to secure primary packaging materials and automated high-speed inspection lines.